Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + epirubicin + paclitaxel
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
The combination of cisplatin, epirubicin, and paclitaxel is a multi-agent chemotherapy regimen used primarily in the treatment of advanced epithelial ovarian carcinoma and advanced breast cancer. Cisplatin is a platinum-based chemotherapeutic that forms DNA crosslinks, leading to apoptosis. Epirubicin is an anthracycline that intercalates into DNA and inhibits topoisomerase II, resulting in DNA damage and cell death. Paclitaxel stabilizes microtubules, preventing their depolymerization during cell division, which leads to mitotic arrest and apoptosis. This combination has demonstrated significant antitumor activity with manageable toxicity profiles in clinical studies[1][2][3].
- Other names
- IPEC-GC regimen
02
Targets
DNATOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cisplatin + epirubicin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + epirubicin + paclitaxel.